Synthesis and in vitro binding studies of substituted piperidine naphthamides.: Part I:: Influence of the substitution on the basic nitrogen and the position of the amide on the affinity for D2L, D4.2, and 5-HT2A receptors

被引:10
作者
Carato, Pascal
Graulich, Amaury
Jensen, Niels
Roth, Bryan L.
Liegeois, Jean-Francois
机构
[1] Univ Liege, Drug Res Ctr, Med Chem Lab, B-4000 Liege 1, Belgium
[2] Fac Sci Pharmaceut & Biol Lille, Chim Therapeut Lab, F-59006 Lille, France
[3] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Sch Med, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA
关键词
D-4.2; receptors; 5-HT2A receptors; antagonist; schizophrenia;
D O I
10.1016/j.bmcl.2006.12.096
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 1- and 2-naphthamides has been prepared and tested for in vitro binding to D-2L, D-4.2, and 5-HT2A receptors. Different compounds display selectivity for D-4.2 and 5-HT2A receptors versus D-2L receptors. N-(1-Arylalkyl-piperidin-4-yl) carboxamides have higher affinities than the corresponding N-(4-arylalkylamino-piperidin-1-yl) carboxamide analogues. A benzyl moiety in position 1 of the piperidine in the 2-naphthamide series (2) appears to be the best choice for a favorable interaction with D-4.2 and 5-HT2A receptors. Increasing the linker length between the phenyl ring and the basic nitrogen led to a decreased affinity for these receptors. In the 1-naphthamide series, the most potent D-4.2 ligand (7) possesses a phenylpropyl moiety while its affinity for 5-HT2A receptors is strongly reduced. All compounds with significant affinity for D-4.2 and 5-HT2A receptors were antagonists. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1565 / 1569
页数:5
相关论文
共 28 条
[1]   N-[(3S)-1-benzylpyrrolidin-3-yl]-(2-thienyl)benzamides:: Human dopamine D4 ligands with high affinity for the 5-HT2A receptor [J].
Arora, J ;
Bordeleau, M ;
Dube, L ;
Jarvie, K ;
Mazzocco, L ;
Peragine, J ;
Tehim, A ;
Egle, I .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (23) :5253-5256
[2]   Design and synthesis of 2-naphthoate esters as selective dopamine D-4 antagonists [J].
Boyfield, I ;
Brown, TH ;
Coldwell, MC ;
Cooper, DG ;
Hadley, MS ;
Hagan, JJ ;
Healy, MA ;
Johns, A ;
King, RJ ;
Middlemiss, DN ;
Nash, DJ ;
Riley, GJ ;
Scott, EE ;
Smith, SA ;
Stemp, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (10) :1946-1948
[3]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[4]   Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia:: A placebo-controlled trial [J].
Corrigan, MH ;
Gallen, CC ;
Bonura, ML ;
Merchant, KM .
BIOLOGICAL PSYCHIATRY, 2004, 55 (05) :445-451
[5]  
DAVIES MA, 2005, PHARMACOGENOMICS J
[6]   JL 13, an atypical antipsychotic:: A preclinical review [J].
Ellenbroek, BA ;
Liégeois, JF .
CNS DRUG REVIEWS, 2003, 9 (01) :41-56
[7]  
HOGBERG T, 1991, Drugs of the Future, V16, P333
[8]   The dopamine D4 receptor:: a controversial therapeutic target [J].
Hrib, NJ .
DRUGS OF THE FUTURE, 2000, 25 (06) :587-611
[9]   EVALUATION OF THE EFFECTS OF THE ENANTIOMERS OF REDUCED HALOPERIDOL, AZAPEROL, AND RELATED 4-AMINO-1-ARYLBUTANOLS ON DOPAMINE AND SIGMA-RECEPTORS [J].
JAEN, JC ;
CAPRATHE, BW ;
PUGSLEY, TA ;
WISE, LD ;
AKUNNE, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (24) :3929-3936
[10]  
Kapur S, 2000, J PSYCHIATR NEUROSCI, V25, P161